![]() |
|
|
Vol. 292, Issue 3, 838-845, March 2000
Department of Medicine, Division of Cardiology and the EPR Center,
Johns Hopkins University, School of Medicine, Baltimore, Maryland; and
Institute of Organic and Medicinal Chemistry, University of Pécs,
Pécs, Hungary (K.H.)
We investigated the cardioprotective efficacy of a new compound
based on 2,2,5,5-tetramethyl-3-pyrroline-3-carboxamide
(TPC-NH). Biochemical studies using electron
paramagnetic resonance (EPR) spectroscopy suggest that
TPC-NH is a scavenger of reactive oxygen species. In
vitro cellular studies show that TPC-NH protects
isolated cardiomyocytes against oxidative damage caused by superoxide
radicals. Ex vivo EPR studies on the isolated rat heart indicate that
the TPC-NH is metabolically oxidized to the nitroxide
form. Studies were also performed in the isolated rat heart model to
measure the efficacy of TPC-NH and its metabolites in
preventing postischemic reperfusion injury. Serial measurements of
contractile function were performed on hearts subjected to
ischemia-reperfusion. Hearts were either untreated or treated with 50 µM TPC-NH or with its metabolites for 1 min before
ischemia and during the first 5 min of reflow. TPC-NH
showed marked protection with a more than 3-fold increased recovery of
contractile function compared with control hearts, whereas its
oxidative metabolites exhibited significant but lower protection. Thus,
TPC-NH and, to a lesser extent, its oxidation
metabolites exhibit potent membrane-targeted antioxidant action and
exert marked protection against myocardial injury in the postischemic heart.
This article has been cited by other articles:
![]() |
R. Mandal, V. K. Kutala, M. Khan, I. K. Mohan, S. Varadharaj, A. Sridhar, C. A. Carnes, T. Kalai, K. Hideg, and P. Kuppusamy N-Hydroxy-pyrroline Modification of Verapamil Exhibits Antioxidant Protection of the Heart against Ischemia/Reperfusion-Induced Cardiac Dysfunction without Compromising Its Calcium Antagonistic Activity J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 119 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Kutala, M. Khan, R. Mandal, L. P. Ganesan, S. Tridandapani, T. Kalai, K. Hideg, and P. Kuppusamy Attenuation of Myocardial Ischemia-Reperfusion Injury by Trimetazidine Derivatives Functionalized with Antioxidant Properties J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 921 - 928. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, K. Y. Xu, L. Zhou, T. Kalai, J. L. Zweier, K. Hideg, and P. Kuppusamy A Pyrroline Derivative of Mexiletine Offers Marked Protection against Ischemia/Reperfusion-Induced Myocardial Contractile Dysfunction J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 563 - 571. [Abstract] [Full Text] |
||||